Erratum: Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase (The FASEB Journal (2010) 24 (2620-2630) DOI:10.1096/fj.09-152546);Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase

FASEB Journal

Volumn 24, Issue 8, 2010, Pages 2620-2630

  Theodoropoulou, Sofia ^a   Kolovou, Paraskevi E ^b   Morizane, Yuki ^a   Kayama, Maki ^a   Nicolaou, Fotini ^b   Miller, Joan W ^a   Gragoudas, Evangelos ^a   Ksander, Bruce R ^b   Vavvas, Demetrios G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Energy; Eye; Intraocular tumors; Metabolism

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 IODOTUBERICIDIN; ACETYL COENZYME A CARBOXYLASE; ADENOSINE KINASE INHIBITOR; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DIPYRIDAMOLE; ENZYME ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; LC3 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN S6; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; ZMP PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 77955818623     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-152546err     Document Type: Erratum

References (44)

1. Young, J., Smith, M., Roffers, S., Liff, J., and Bunin, G. (2003) Retinoblastoma, National Cancer Institute, Bethesda, MD, USA
2. Gurney, J., Smith, M., and Ross, J. (2003) Cancer Among Infants, National Cancer Institute, Bethesda, MD, USA
3. Broaddus, E., Topham, A., and Singh, A. D. (2009) Survival with retinoblastoma in the USA: 1975-2004. Br. J. Ophthalmol. 93, 24-27
4. Rodriguez-Galindo, C., Wilson, M. W., Haik, B. G., Lipson, M. J., Can, A., Merchant, T. E., Kaste, S., and Pratt, C. B. (2003) Treatment of metastatic retinoblastoma. Ophthalmology 110, 1237-1240
5. Roarty, J. D., McLean, I. W., and Zimmerman, L. E. (1988) Incidence of second neoplasms in patients with retinoblastoma. Ophthalmology 95, 1583-1587
6. Shields, C. L., Ramasubramanian, A., Thangappan, A., Hartzell, K., Leahey, A., Meadows, A. T., and Shields, J. A. (2009) Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology 116, 544-551
7. Shields, C. L., Honavar, S. G., Shields, J. A., Demirci, H., Meadows, A. T., and Naduvilath, T. J. (2002) Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch. Ophthalmol. 120, 460-464
8. Shields, C. L., Shelil, A., Cater, J., Meadows, A. T., and Shields, J. A. (2003) Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch. Ophthalmol. 121, 1571-1576
9. Sussman, D. A., Escalona-Benz, E., Benz, M. S., Hayden, B. C., Feuer, W., Cicciarelli, N., Toledano, S., Markoe, A., and Murray, T. G. (2003) Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Arch. Ophthalmol. 121, 979-984
10. Schefler, A. C., Cicciarelli, N., Feuer, W., Toledano, S., and Murray, T. G. (2007) Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 114, 162-169
11. Shields, C. L. (2008) Forget-me-nots in the care of children with retinoblastoma. Semin. Ophthalmol. 23, 324-334
12. Shields, C. L., Palamar, M., Sharma, P., Ramasubramanian, A., Leahey, A., Meadows, A. T., and Shields, J. A. (2009) Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch. Ophthalmol. 127, 282-290
13. Benz, M. S., Scott, I. U., Murray, T. G., Kramer, D., and Toledano, S. (2000) Complications of systemic chemotherapy as treatment of retinoblastoma. Arch. Ophthalmol. 118, 577-578
14. Nishimura, S., Sato, T., Ueda, H., and Ueda, K. (2001) Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J. Clin. Oncol. 19, 4182-4183
15. Hardie, D. G., and Carling, D. (1997) The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur. J. Biochem. 246, 259-273
16. Hardie, D. G. (2003) The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144, 5179-5183
17. Hardie, D. G., and Sakamoto, K. (2006) AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology 21, 48-60
18. Davies, S. P., Carling, D., and Hardie, D. G. (1989) Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur. J. Biochem. 186, 123-128
19. Kemp, B. E., Stapleton, D., Campbell, D. J., Chen, Z. P., Murthy, S., Walter, M., Gupta, A., Adams, J. J., Katsis, F., van Denderen, B., Jennings, I. G., Iseli, T., Michell, B. J., and Witters, L. A. (2003) AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. 31, 162-168
20. Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Makela, T. P., Alessi, D. R., and Hardie, D. G. (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28
21. Woods, A., Vertommen, D., Neumann, D., Turk, R., Bayliss, J., Schlattner, U., Wallimann, T., Carling, D., and Rider, M. H. (2003) Identification of phosphorylation sites in AMP-activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by site-directed mutagenesis. J. Biol. Chem. 278, 28434-28442
22. Nakanishi, C., Yamaguchi, T., Iijima, T., Saji, S., Toi, M., Mori, T., and Miyaki, M. (2004) Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. Oncology 67, 476-479
23. Inoki, K., Zhu, T., and Guan, K. L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590
24. Luo, Z., Saha, A. K., Xiang, X., and Ruderman, N. B. (2005) AMPK, the metabolic syndrome and cancer. Trends Pharmacol. Sci. 26, 69-76
25. Rattan, R., Giri, S., Singh, A. K., and Singh, I. (2005) 5-Aminoimidazole-4-carboxide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 280, 39582-39593
26. Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y. X., Banayo, E., Mihaylova, M. M., Nelson, M. C., Zou, Y., Juguilon, H., Kang, H., Shaw, R. J., and Evans, R. M. (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134, 405-415
27. Russell, R. R., Li, J., Coven, D. L., Pypaert, M., Zechner, C., Palmeri, M., Giordano, F. J., Mu, J., Birnbaum, M. J., and Young, L. H. (2004) AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 114, 495-503
28. Ido, Y., Carling, D., and Ruderman, N. (2002) Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 51, 159-167
29. Culmsee, C., Monnig, J., Kemp, B. E., and Mattson, M. P. (2001) AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 17, 45-58
30. Baumann, P., Mandl-Weber, S., Emmerich, B., Straka, C., and Schmidmaier, R. (2007) Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp. Cell Res. 313, 3592-3603 (Pubitemid 47404540)
31. Garcia-Gil, M., Pesi, R., Perna, S., Allegrini, S., Giannecchini, M., Camici, M., and Tozzi, M. G. (2003) 5′-aminoimidazole-4-carboxamide riboside induces apoptosis in human neuroblastoma cells. Neuroscience 117, 811-820
32. Guo, D., Hildebrandt, I. J., Prins, R. M., Soto, H., Mazzotta, M. M., Dang, J., Czernin, J., Shyy, J. Y., Watson, A. D., Phelps, M., Radu, C. G., Cloughesy, T. F., and Mischel, P. S. (2009) The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc. Natl. Acad. Sci. U. S. A. 106, 12932-12937
33. Sengupta, T., Leclerc, G., Hsieh-Kinser, T., Leclerc, G., Singh, I., and Barredo, J. (2007) Cytotoxic effect of 5-aminoimidazole-4-carboxamide-I-β- 4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol. Cancer 6, 46
34. Su, R. Y., Chao, Y., Chen, T. Y., Huang, D. Y., and Lin, W. W. (2007) 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNFα-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol. Cancer Ther. 6, 1562-1571
35. Zang, Y., Yu, L. F., Nan, F. J., Feng, L. Y., and Li, J. (2009) AMP-activated protein kinase is involved in neural stem cell growth suppression and cell cycle arrest by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and glucose deprivation by down-regulating phospho-retinoblastoma protein and cyclin D. J. Biol. Chem. 284, 6175-6184
36. Robert, G., Ben, S. I., Puissant, A., Colosetti, P., Belhacene, N., Gounon, P., Hofman, P., Bost, F., Cassuto, J. P., and Auberger, P. (2009) Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One 4, e7889
37. López, J. M., Santidrián, A. F., Campàs, C., and Gil, J. (2003) 5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMP-activated protein kinase is not involved. Biochem. J. 370, 1027-1032
38. Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M., and Esumi, H. (2001) Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D- ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 287, 562-567
39. Gartel, A. L. (2009) p21(WAF1/CIP1) and cancer: a shifting paradigm? Biofactors 35, 161-164
40. Gartel, Al., and Radhakrishnan, S. K. (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65, 3980-3985
41. MacPherson, D., Sage, J., Kim, T., Ho, D., McLaughlin, M. E., and Jacks, T. (2004) Cell type-specific effects of Rb deletion in the murine retina. Genes Dev. 18, 1681-1694
42. Zhang, J., Schweers, B., and Dyer, M. A. (2004) The first knockout mouse model of retinoblastoma. Cell Cycle 3, 952-959
43. MacPherson, D., Conkrite, K., Tam, M., Mukai, S., Mu, D., and Jacks, T. (2007) Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO J. 26, 784-794
44. Sag, D., Carling, D., Stout, R. D., and Suttles, J. (2008) Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181, 8633-8641